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Introduction: The importance of -2-glycoprotein 1, zinc (AZGP1)
in lung adenocarcinoma (AD) remains largely unknown. Analysis of
serum autoantibodies to tumor antigens combined with gene expres-
sion profiling of primary tumors may provide insight into the
mechanisms underlying lung carcinogenesis and identify new AD
biomarkers.
Methods: T7 phage cDNA libraries were used to identify AZGP1
autoantibodies in the serum of 473 patients (192 ADs, 192 matched
controls, and 89 additional ADs for confirmation of findings).
AZGP1 mRNA expression was examined in 86 ADs and 10 control
lung tissue samples using oligonucleotide microarrays. AZGP1
protein expression was studied in 230 tissue samples (222 ADs; 8
controls) with immunohistochemistry. Kaplan-Meier analyses were
used to correlate circulating autoantibody and tissue mRNA produc-
tion with survival. AD cell lines A549 and SKLU1 were treated with
5-aza-2-deoxycytidine (5-AZA) and trichostatin A (TSA) to exam-
ine the role of promoter methylation and histone deacetylation in the
expression of AZGP1. Real-time polymerase chain reaction was
used to quantify the effects of treatment.
Results: In patients with AD, AZGP1 autoantibodies were observed
in 40% of serum samples. Autoantibody production correlated with
improved overall 5-year survival (p 0.002) and improved survival
in those with stage I to II disease (p 0.008). A verification analysis
was performed for the survival benefit and found similar results with
p values of 0.02 and 0.036, respectively. Although abundant mRNA
expression was found in a subset of tumors, mRNA expression did
not correlate with prognosis. In normal lung, AZGP1 mRNA and
protein expression were low or absent, whereas in AD they were
highly expressed in 31.3% and 42.8% of samples, respectively. To
determine whether AZGP1 expression in this subset of tumors might
be affected by epigenetic mechanisms, low AZGP1-expressing A549
and SKLU1 AD cell lines were treated with TSA and 5-AZA. A
713-fold and 169-fold increase in mRNA expression were noted on
treatment with TSA, respectively. Treatment with 5-AZA had min-
imal effect on AZGP1 mRNA expression.
Conclusions: The presence of AZGP1 serum autoantibody may be
used as a prognostic marker in patients with AD. Furthermore,
up-regulation of AZGP1 mRNA in AD may be affected by chroma-
tin remodeling by means of histone acetylation.
Key Words: Lung adenocarcinoma, Autoantibody, AZGP1, Epige-
netic regulation.
(J Thorac Oncol. 2008;3: 1236–1244)
Lung cancer is currently the leading cause of cancer deathin industrialized nations, with a 5-year survival of approx-
imately 15%.1 Among non-small cell lung cancer variants,
adenocarcinoma (AD) is the most common histologic sub-
type. DNA microanalysis has allowed for the simultaneous
expression analysis of thousands of genes, and has been used
extensively to correlate lung AD tumor expression patterns
with clinical outcomes.2 Analysis of serum autoantibodies to
tumor antigens combined with gene expression profiling of
primary tumors may provide insight into the mechanisms
underlying carcinogenesis and identify new biomarkers in
lung AD. We have used this approach to study one potential
candidate, -2-glycoprotein 1, zinc (AZGP1).
The importance of AZGP1 and its 41 kDa soluble
protein product (also known as ZAG) in neoplastic progres-
sion in general, or lung cancer specifically, remains largely
unknown. In 2007, AZGP1 gene expression in normal lung
tissue from patients with AD was shown to correlate to
disease status,3 suggesting that AZGP1 may be useful as a
marker of lung cancer susceptibility. AZGP1 plays a role in
lipid mobilization in mice, and may contribute to malignancy-
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associated cachexia.4 Conversely, in prostate cancer, low or
absent AZGP1 expression in radical prostatectomy specimens
has been associated with cancer recurrence.5 Likewise,
AZGP1 levels correlate with degree of differentiation in 40%
of breast carcinomas.6 Interestingly, AZGP1 also shares sig-
nificant structural similarity with the major histocompatibility
complex class I family of peptides,7 the significance of which
is unknown.
In the current study, we identified a high frequency of
AZGP1 autoantibodies while screening patient serum with T7
phage display cDNA libraries. Although autoantibody pro-
duction did not predict the presence of lung AD, the level of
autoantibody correlated with improved overall 5-year sur-
vival, improved survival in patients with stage I to II disease
and was shown to be an independent predictor of survival on
multivariate analysis. These findings prompted us to examine
the mRNA and protein expression profiles of AZGP1 in a
large series of primary lung tumors and two AD cell lines.
We found that 30 to 40% of AD overexpressed AZGP1 at
both the mRNA and protein level. Furthermore, our in vitro
studies suggest that histone acetylation contributes to the
overexpression of AZGP1 in this subset of tumors.
PATIENTS AND METHODS
Patient Population and Samples
This study was approved by the Institutional Review
Board of the University of Michigan (UM) Medical School
and the University of Pittsburgh (UP). For autoantibody
screening, sera from 194 patients with AD were collected at
the time of surgery between November 1996 and July 2005 at
the UM Health System (UMHS). All of the primary tumor
sections were evaluated by a study pathologist and clinical
information was collected (Tables 1 and 3). All patient
identifiers were coded to protect confidentiality. As noncan-
cer control subjects, 102 serum samples (including 40 benign
lung disease and 62 healthy controls) with no known history
of cancer were collected from the UMHS Clinical Pathology
laboratories. These samples were collected between 2001 and
2004 in three independent collection periods (Table 1). No
patients in this cohort received chemical or radiation treat-
ment before the sera were collected. All sera are stored in
aliquots at 80°C until use.
An independent cohort of sera for autoantibody screen-
ing from 87 histologically confirmed and untreated primary
AD and 90 control patients, matched for both age and
smoking status, collected between 2000 and 2005, was col-
lected at the UP Cancer Institute/Hillman Cancer Center
(Table 1).
The oligonucleotide microarray and tissue microarray
(TMA) specimens were obtained from patients who under-
went surgery for primary AD at the UMHS between 1994 and
2000. Tissues were transported on ice in Dulbecco Modified
Eagle Medium (DMEM; Life Technologies, Inc., Carlsbad,
CA), immediately frozen in liquid nitrogen, and stored at
80°C. Tissues demonstrating AD and at least 70% tumor
cellularity were identified on hematoxylin and eosin-stained
frozen sections. Microdissection was used to obtain samples
2 to 3 mm3 in size for RNA and protein isolation. The
histologic diagnosis of each specimen was independently
confirmed by two pathologists (T.J.G and D.G.T).
Autoantibody Detection
The detailed methods for construction of T7 phage
display lung cancer cDNA libraries, amplification of libraries,
biopanning for phage-epitope clones specific to lung cancer
and noncancer controls, and sequence analysis of humoral
immune response targets were carried out as previously
reported.8
Oligonucleotide Microarray
The RNA was isolated and cRNA synthesized and
analyzed for oligonucleotide microarray as described previ-
ously.9 Results from this data set have been previously
published elsewhere.2
Immunohistochemistry (IHC) and TMA
Immunohistochemical staining was performed on the
DAKO Autostainer (DAKO, Carpinteria, CA) using DAKO
LSAB and diaminobenzadine as the chromogen, as previ-
ously described.9 Deparaffinized sections of the TMA pre-
pared as previously described,10 at 5-m thickness were
labeled with AZGP1 antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, Cat SC-13585, mouse, 1:400) after micro-
wave antigen retrieval in 10 mM sodium citrate buffer, pH 6.
Appropriate negative (no primary antibody) and positive
(prostate carcinoma TMA) controls were stained with each
immunohistochemical assay. The immunoreactivity was
scored on a four-tier (negative [0], weak [1], intermediate
[2], or strong [3]) grading scheme. Both intensity and
extent of staining were used in grading the tissue samples.
TABLE 1. Clinical and Demographic Information for UMHS
and UP Patients and Controls Screened for Autoantibody
Production Summarizing Age, Sex, Stage, and Survival
Clinical Information for
UMHS Samples
Clinical Information for
UP Samples
Adenocarcinomas (n) 105 Adenocarcinomas (n) 87
Age average (yr) 66.4 Age average (yr) 67
Age range (yr) 43–85 Age range (yr) 42–82
Male (n) 49 Male (n) 34
Female (n) 56 Female (n) 53
Stage I (n) 70
Stage II (n) 18
Stage III  IV (n) 17
Dead (n) 50
Alive (n) 55
Survival time average (mo) 35.2
Noncancer control (n) 102 Noncancer control (n) 90
Age average (yr) 55 Age average (yr) 65
Age range (yr) 33–80 Age range (yr) 50–83
Male (n) 49 Male (n) 40
Female (n) 52 Female (n) 50
The gender of one noncancer UMHS control patient was not available. There are no
significant differences in the demographics of the lung AD patients and the control
subjects from either population.
AD, lung adenocarcinoma; UMHS, University of Michigan Health System; UP,
University of Pittsburgh.
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Cell Lines and Treatment
A549 AD cells were grown and treated in DMEM (Cat.
11965; Invitrogen Corporation, Carlsbad, CA) and F12-
Kaighn’s media (Cat. 21127; Invitrogen Corp.) with 10%
fetal bovine serum (FBS) at 37°C in 5% CO2. SKLU1 AD
cells were grown and treated in DMEM (Cat. 11965; Invitro-
gen Corp.) with 10% FBS at 37°C in 5% CO2. All cell lines
were serum-starved for 24 hours before treatment to synchro-
nize their cell cycles. Cell lines were treated with trichostatin
A (TSA) at a final concentration of 300 nM or 5-aza-2’-
deoxyctidine (5-AZA) at a final concentration of 5 M in
media containing 10% FBS. Cells receiving combination
treatment were exposed to both 300 nM TSA and 5 M
5-AZA. TSA and 5-AZA were dissolved in dimethyl sulfox-
ide and control cells were treated with equivalent amounts of
dimethyl sulfoxide. Control cells were harvested at 24, 48,
72, and 96 hours and compared with cells treated for the same
length of time. Cells treated with TSA were trypsinized and
harvested at 12 and 24 hours and those treated with 5-AZA
were harvested at 48, 72 and 96 hours. Combination plates
were treated with 5-AZA for 48, 72 or 96 hours and TSA for
24 hours. Cell pellets were frozen in liquid nitrogen and
stored in 80°C until further use.
Real-Time Reverse Transcription-Polymerase
Chain Reaction (RT-PCR)
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Valencia, CA) according to the manufacturer’s in-
structions. Real-time RT-PCR was performed using the
Rotor-Gene 6000 (Corbett Life Science, Sydney, Australia)
with the Platinum SYBR Green kit (Invitrogen Corp.) accord-
ing to the manufacturer’s instructions. Primer sequences for
real-time RT-PCR for AZGP1 were obtained from Invitrogen
and included primer ZAG-1f1 (AGG CCA GGG AGG ACA
TCT TTT ATG) and primer ZAG-1r1 (AAT GCT CCG CTG
CTT CTG TTA TTC). Glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) expression was used to standardize the
AZGP1 results using GAPDH primer f43 and primer r152.
Optimal annealing temperatures were determined, and melt
curves were analyzed to ensure specificity of the RT-PCR
FIGURE 1. Levels of AZGP1 auto-
antibody detected in (A) AD and (B)
control subjects. The first 140 AD
patients showed an autoantibody
level of 2 whereas the first 139
control patients showed a level 2.
A similar number of patients in each
subset showed a level of AZGP1 au-
toantibody that was 2. AD, lung
adenocarcinoma.
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results. All real-time RT-PCR experiments were repeated in
triplicate.
Western Blot Analysis
Western blot analysis was performed as previously
described with slight variations.11 Briefly, 10 L of serum,
diluted at 1:10 serum to deionized water, was loaded onto a
10% SDS polyacrylamide gel and electrophoresed. A 1:500
or 1:1000 concentration of primary AZGP1 antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, Cat SC-13585, mouse,)
and a 1:5000 or 1:10,000 concentration of secondary anti-
body (NA931V goat antimouse, GE Healthcare U.K. Lim-
ited, Chalfont St. Giles, U.K.) was used for protein detection.
No positive control was performed because these blots were
carried out to determine whether AZGP1 autoantibody pro-
duction correlated with the presence of AZGP1 protein in the
serum.
Correlation Between AZGP1 and Histone
Deacetylase (HDAC) and Histone
Acetyltransferase (HAT) Expression
To examine the potential role of histone acetylation in
the regulation of AZGP1 expression, we examined the oligo-
nucleotide microarray expression of HDACs and HATs. How-
ever, the Affymetrix HuFL microarray2 included only three
HDAC probe sets: HDAC1, HDAC2, and HDAC3. Therefore,
we repeated the analysis with three publicly available expres-
sion data sets that used the Affymetrix HG-U133A oligonu-
cleotide microarray. These data were obtained from the Gene
Expression Omnibus.12 One of the data sets used included
primary lung AD and normal lung tissue,13 whereas the
second included primary lung AD and lung squamous cell
carcinomas.14 The third contained only primary lung adeno-
carcioma data.15 For the first data set, all normal lung tissue
data were excluded and for the second data set all squamous
cell carcinoma data were excluded before analysis.
Statistical Analysis
Kaplan-Meier survival curve and log-rank tests were
used to determine patient survival associated with the pres-
ence of the AZGP1 autoantibody. A Cox proportional haz-
ards model was used to perform a multivariate survival
analysis. The log-transformed expression values obtained
from the oligonucleotide microarrays were used to perform
Spearman correlation analysis between the continuous
mRNA expression values and categorical protein expression
value (defined as 0, 1, 2, 3) for 72 patients. Spearman
analysis was also used to correlate AZGP1 gene expression
with that of the HDACs and HATs. The t test was used to
determine the significance of AZGP1 mRNA up-regulation
after treatment with TSA. A p value0.05 was deemed to be
significant.
RESULTS
AZGP1 Autoantibody Predicts Survival
Demographic and outcome data for the 384 patients and
controls from the UM and UP screened for autoantibody
production are outlined in Table 1. The level of AZGP1
autoantibody detected is demonstrated in Figure 1. There was
no difference in the frequency or quantity of autoantibody
production between AD patients and controls. In control
patients, 38% produced AZGP1 autoantibody, with a maxi-
mum relative production of 78.3, an average of 3.85, and a
median of 0.99. In AD patients, 40.1% produced the autoan-
tibody, with a maximum value of 77.6, an average of 3.75,
and a median of 1.00. In addition, no relationship existed
FIGURE 2. A, Kaplan-Meier survival analysis for AZGP1 au-
toantibody in AD patients. Patients with high levels of
AZGP1 autoantibody (level median 1.02) had significantly
better 5-year survival than patients with low levels of AZGP1
autoantibody (p  0.002). B, Kaplan-Meier survival curve
analysis for AZGP1 autoantibody production in patients with
stage I and II AD. Patients with high levels (level median
1.02) of autoantibody had significantly better 5-year survival
than patients with low levels (p  0.008). AD, lung adeno-
carcinoma.
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between autoantibody production and smoking, age, sex, or
tumor differentiation. On Kaplan-Meier survival analysis of
AD patients, the level of autoantibody correlated with sur-
vival (p  0.002) (Figure 2A). As an inverse correlation
between stage and level of autoantibody existed (p  0.011),
we performed Kaplan-Meier analysis on stage I to II patients
alone, and found that the survival benefit remained (p 
0.008) in this subset of early stage cases (Figure 2B). To
confirm that stage was not a confounding variable, we used a
Cox proportional hazards model to perform a multivariate
analysis that included stage and AZGP1 autoantibody level.
This analysis demonstrated that stage was an independent
predictor of prognosis (p  0.03), as would be expected.
However, AZGP1 autoantibody level greater than the median
was confirmed to be a strong independent predictor of prog-
nosis (p  0.009). We also analyzed an additional 89 serum
samples from patients with AD seen at the UM to verify
the survival benefit in an independent set of patients. The
demographic and outcome of these patients can be seen in
Table 2. Confirming previous results, looking at all pa-
tients, the patients with high levels of AZGP1 autoanti-
body had better outcome (p  0.02). In addition, when
examining only patients with stage I/II tumors the survival
benefit remained (p  0.036). These curves can be seen in
Figures 3A, B.
AZGP1 mRNA Is Overexpressed in a Subset of
Lung ADs
Oligonucleotide microarrays were used to examine a
cohort of 86 AD and 10 normal lung tissues. We found 31.3%
of AD samples expressed AZGP1 mRNA at levels at least
two fold higher than the mean of the controls (Figure 4).
AZGP1 Protein Is Expressed in a Subset of
Lung ADs, But Not in Normal Lung
IHC was used to examine AZGP1 protein expression
in 230 lung tissue samples (222 ADs; 8 controls) (Figure
5). Expression of AZGP1 protein was identified in 42.8%
of AD samples, whereas no normal tissues showed expres-
sion (Table 3). All AZGP1 staining was cytoplasmic and
no correlation was noted between intensity of staining and
differentiation or subtype of AD. We also found a signif-
icant positive correlation between mRNA expression on
oligonucleotide microarray and protein expression on IHC
(p  0.006).
TABLE 2. Clinical and Demographic Information for UMHS
Patients Used to Verify Survival Benefit of High Levels of
Autoantibody Screened for Autoantibody Production
Summarizing Age, Sex, Stage, and Survival
Clinical Information for UMHS Survival Verification Samples
Adenocarcinomas (n) 89
Age average (yr) 64.8
Age range (yr) 34–90
Male (n) 49
Female (n) 40
Stage I  II (n) 68
Stage III  IV (n) 21
Dead (n) 42
Alive (n) 47
Survival time average (mo) 48.2
There are no significant differences between the demographics of these 89 lung AD
patients and the 105 lung AD patients used in the initial analysis.
AD, lung adenocarcinoma; UMHS, University of Michigan Health System.
FIGURE 3. A, Verification of Kaplan-Meier survival analysis
for AZGP1 autoantibody in AD patients. Patients with high
levels of AZGP1 autoantibody (level median 1.02) has sig-
nificantly better 5-year survival than patients with low levels
of autoantibody (p  0.02). B, Verification of Kaplan-Meier
survival analysis for AZGP1 autoantibody production in
patients with stage I and II AD. Patients with high levels
(level median 1.02) of autoantibody had significantly bet-
ter 5-year survival than patients with low levels (p  0.036).
AD, lung adenocarcinoma.
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Serum AZGP1 Protein Levels Were Unrelated
to Primary Tumor AZGP1 Protein Expression or
AZGP1 Autoantibody Production
The ubiquitous presence of AZGP1 protein in human
serum was confirmed with Western blot analysis of serum
from patients with primary tumor samples available (Fig-
ure 6A). No relationship was seen between AZGP1 protein
expression in the primary tumor and serum AZGP1 pro-
tein, as all serum samples demonstrated the presence of
AZGP1 protein. On Western blot analysis of patient serum,
no relationship was seen between serum AZGP1 protein
level and autoantibody production. AZGP1 protein was
detected in all serum samples irrespective of autoantibody
production, cancer status, or presence of benign lung
disease (Figure 6B).
Histone Deacetylation Inhibition May
Up-Regulate AZGP1 Transcription
We treated AD cell lines A549 and SKLU1 with
5-AZA and TSA to determine whether epigenetic regulation
affected AZGP1 expression. On real-time RT-PCR, A549 had
a baseline AZGP1 Ct  27.7 and a GAPDH Ct  11.0;
SKLU1 had a baseline Ct  30.4 and a GAPDH Ct  10.3.
A 713-fold and 169-fold increase in mRNA expression was
noted on TSA treatment of A549 (Figure 7A) and SKLU1
cells (Figure 7B), respectively. In both cell lines, treatment
with 5-AZA had an attenuating effect on AZGP1 mRNA
expression, with mRNA suppression directly related to dura-
tion of 5-AZA exposure from 48 to 96 hours.
Correlation Between AZGP1 and MYST1,
HDAC1, HDAC2, and HDAC4 Expression
We compared the expression of HDAC1, HDAC2, and
HDAC3 on the original oligonucleotide microarray with
AZGP1 expression using Spearman correlation analysis and
found no correlation (p  0.63, 0.20, and 0.68, respectively).
We then performed the analysis using three publicly available
Affymetrix HG-U133A lung cancer data sets. A significant
positive correlation was found between AZGP1 and MYST1
expression in two of the data sets14,15 (p  0.0001 and p 
0.036, respectively). In addition, negative correlations were
noted between AZGP1 and HDAC1 in two data sets13,14
(p  0.02 and p  0.02, respectively). Furthermore, in the
second data set,14 AZGP1 and HDAC2 had a significant
negative correlation (p  0.022), as did AZGP1 and
HDAC4 (p  0.041).
DISCUSSION
During screening for autoantibodies in the serum of
lung AD patients and controls, we found the AZGP1 auto-
antibody to be frequently and highly detected. The prevalence
in both cancer and control groups indicates that the AZGP1
autoantibody will not be useful as a diagnostic tool, but its
presence may have prognostic value. When all AD patients,
as well as stage I and II AD patients, were independently
examined, those with high levels of this autoantibody had
lower 5-year mortality. It is unlikely that the autoantibody
itself is protective against the development of AD, as control
and cancer patients produced it in similar quantities. There-
fore, the presence of an AZGP1 autoantibody can only be
regarded as marker for improved prognosis once a patient
develops lung AD. Further investigation into the underlying
FIGURE 4. Oligonucleotide mi-
croarray analysis of 86 AD and 10
normal samples revealed that
31.3% of adenocarcinomas ex-
pressed AZGP1 at least two fold
more than the controls. Samples 1
to 86, AD; samples 87 to 96, con-
trols. AD, lung adenocarcinoma.
FIGURE 5. AZGP1 protein staining was not detected in (A)
normal lung tissues, but was seen in (B) and (C) 42.8% of
AD, and (D) 8.3% of SCC by immunohistochemistry. AD,
lung adenocarcinoma; SCC, lung squamous cell carcinoma.
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mechanism of AZGP1 autoantibody production, including
the homology of AZGP1 to the major histocompatibility
protein family,7 may lead to a better understanding of the
development of autoantibodies to tumor antigens.
The physiologic basis for the anti-AZGP1 autoantibody
acting as a prognostic marker is unknown, as its production is
independent of serum protein presence. There is mounting
evidence that the immune system plays a role in identifying
and suppressing cancer.16–25 The production of anti-AZGP1
autoantibodies may be an indicator of the overall fidelity or
reactivity of an individual’s immune surveillance system.
This increased immune reactivity may not be sufficient to
prevent the development of cancer, but may impart some
protective effect in those who later develop AD.
The prognostic utility of the AZGP1 autoantibody com-
bined with recent reports that AZGP1 mRNA levels have
diagnostic value3 prompted us to examine AZGP1 mRNA
and protein production in primary AD tissues and two AD
cell lines. Our data suggest that the overexpression observed
in this subset of primary tumors might be explained by
histone deacetylation inhibition. The observed resistance of
A549 cells to demethylation by 5-AZA is also consistent with
previous reports26; SKLU1 cells demonstrated a similar, but
attenuated, response to 5-AZA treatment. Previous reports
have established that epigenetic mechanisms significantly
affect patterns of gene expression in normal and neoplastic
tissue.27–29 However, 5-AZA and TSA are globally acting
agents and exposure may regulate other genes that affect
AZGP1 transcription. Whether TSA acts directly on AZGP1
or somewhere upstream is somewhat inconsequential because
the end result is an increase in expression of AZGP1. Con-
sistent with some role of histone modification in AZGP1
expression, several publicly available databases revealed pos-
itive correlations between AZGP1 expression and MYST1,
a HAT, and negative correlations with several HDAC
genes.12–15
Although there was a significant correlation between
mRNA and protein production in primary AD tissues, this
was not observed on Western blot and IHC of A549 and
SKLU1 cells treated with TSA. However, this finding was not
completely unexpected as 8.3% (6 of 72) of primary tumors
examined by oligonucleotide microarray and TMA overex-
pressed AZGP1 mRNA but not AZGP1 protein. The mecha-
nism for this disconnect is not clear, however, the low
baseline production of AZGP1 mRNA in A549 and SKLU1
cells may allow for a significant relative up-regulation of
mRNA, but an absolute increase that does not translate into a
detectable difference in protein production. Detection of
AZGP1 protein expression in 42.8% of the AD specimens,
but not in TSA-treated A549 or SKLU1 cells, may also reflect
differences between the in vivo and in vitro microenviron-
ment. Another explanation for the mRNA-protein disconnect
may be posttranscriptional interference. There are four micro-
RNAs predicted to bind to the AZGP1 mRNA, suggesting an
area for future investigation.30
Previous reports have indicated a relationship between
AZGP1 production and secretory function,31 which we con-
firmed in an analysis of a wide variety of normal tissues by
means of TMA. Consistent with this, we found that AD had
significantly higher AZGP1 expression than primary lung
squamous cell carcinoma. However, we noted that this rela-
tionship is not consistent across all tissues. For example, type
II pneumocytes, which are known to have surfactant secre-
tory function in normal lung tissue, demonstrate no AZGP1
production (Figure 5A). Other secretory tissues that do not
express AZGP1 include adrenal medulla and corpus luteum
TABLE 3. Immunohistochemical Analysis Revealed 42.8% of AD with AZGP1 Protein Expression, But Not Samples of
Normal Lung
Tissue type Total samples
No. of expression
(n)
Weak expression
(n)
Intermediate expression
(n)
Strong expression
(n)
Total with expression
(n)
AD 222 57.2% (127) 30.1% (67) 7.2% (16) 5.4% (12) 42.8% (95)
Control 8 100% (8) 0% 0% 0% 0%
AD, lung adenocarcinoma.
FIGURE 6. A, Western blot demonstrating AZGP1 protein in the serum of all patients, irrespective of AZGP1 protein staining
on tissue microarrays. AD, patient with lung adenocarcinoma; N, normal control subject; NE, no AZGP1 protein expression on
TMA (negative); WE, weak AZGP1 expression (1); IE, intermediate AZGP1 expression (2); SE, strong AZGP1 expression
(3). B, Western blot demonstrating AZGP1 protein in the serum of all patients, irrespective of AZGP1 autoantibody produc-
tion. AD, patient with lung adenocarcinoma; N, normal control subject; BL, patient with benign lung disease; Low, patient
with serum autoantibody level  2; High, patient with serum autoantibody level  2.
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(data not shown). Therefore, it appears a more complex
relationship exists between AZGP1 and secretory cell types
than previously reported.
In conclusion, we have found that serum autoantibodies
to AZGP1 are abundant and correlate with improved outcome
in patients with AD. Further elucidating the function of
AZGP1 in AD may provide insight into why AZGP1 auto-
antibody presence predicts survival in patients who develop
lung cancer, but does not prevent the disease. In addition, our
data suggest that epigenetic regulation by means of histone
deacetylation inhibition plays a role in AZGP1 expression,
which may account for the up-regulation observed in some
AD. This study provides data to support the continued inves-
tigation of AZGP1 in neoplastic development.
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FIGURE 7. A, AZGP1 mRNA pro-
duction is up-regulated in a time
dependent manner by HDAC inhibi-
tor TSA in A549 cells. Gene pro-
moter demethylation by 5-AZA has
no effect on AZGP1 mRNA expres-
sion in A549 and attenuates the up-
regulation by TSA. B, AZGP1 mRNA
production is up-regulated in a time
dependent manner by HDAC inhibi-
tor TSA in SKLU1 cells. Gene pro-
moter demethylation by 5-AZA has
no effect on AZGP1 mRNA expres-
sion in SKLU1 cells and attenuates
the up-regulation by TSA. TSA, tri-
chostatin A; 5-AZA, 5-aza-2’ deoxy-
cytidine. *p  0.05 with t test as
compared with control.
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